| 5671 |
Success stories, learnings on ACSM for TB elimination |
02/06/2024 |
Community engagement and call centre |
| 5640 |
National TB Call Centre Support: Ni-kshay Sampark |
02/06/2024 |
Community engagement and call centre |
| 5613 |
Deliverable verification and payment process: Payment |
02/06/2024 |
Community engagement and call centre |
| 28 |
Adverse Drug Reactions |
02/06/2024 |
DR-TB and PMDT |
| 100 |
DR-TB Centres and Network |
02/06/2024 |
DR-TB and PMDT |
| 251 |
Screening and Diagnosis for DRTB |
02/06/2024 |
DR-TB and PMDT |
| 274 |
Counselling |
02/06/2024 |
DR-TB and PMDT |
| 277 |
Counselling of TB Patients at Various Stages of Treatment |
02/06/2024 |
DR-TB and PMDT |
| 278 |
Nutritional Counselling |
02/06/2024 |
DR-TB and PMDT |
| 279 |
Counselling for regular follow-up during the treatment |
02/06/2024 |
DR-TB and PMDT |
| 280 |
Counselling for TB treatment initiation |
02/06/2024 |
DR-TB and PMDT |
| 354 |
Burden of DR-TB in India |
02/06/2024 |
DR-TB and PMDT |
| 625 |
Adverse Drug Reactions(ADRs) to First Line Treatment |
02/06/2024 |
DR-TB and PMDT |
| 626 |
Adverse Drug Reactions(ADRs) to Second Line Treatment |
02/06/2024 |
DR-TB and PMDT |
| 629 |
Screening for DR-TB |
02/06/2024 |
DR-TB and PMDT |
| 630 |
DR-TB Treatment Regimens |
02/06/2024 |
DR-TB and PMDT |
| 729 |
Integrated DR-TB Algorithm |
02/06/2024 |
DR-TB and PMDT |
| 745 |
Pharmacovigilance in NTEP |
02/06/2024 |
DR-TB and PMDT |
| 749 |
Prevention of Drug Resistance |
02/06/2024 |
DR-TB and PMDT |
| 771 |
Types of Drug Resistance Tuberculosis -DRTB |
02/06/2024 |
DR-TB and PMDT |
| 772 |
Pre treatment evaluation of a DRTB cases |
02/06/2024 |
DR-TB and PMDT |
| 977 |
List of Drugs that can be Used Safely or Avoided along with Bedaquiline |
02/06/2024 |
DR-TB and PMDT |
| 979 |
Use of Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen in Special Situations |
02/06/2024 |
DR-TB and PMDT |
| 983 |
Eligibility Criteria for Longer Oral M/XDR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 984 |
Treatment Extension in Isoniazid [H] Mono/Poly DR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 987 |
Management of DR-TB ADR: Gastrointestinal Symptoms [Gastritis and abdominal pain] |
02/06/2024 |
DR-TB and PMDT |
| 988 |
Management of DR-TB ADR: Diarrhoea and/or Flatulence |
02/06/2024 |
DR-TB and PMDT |
| 999 |
Management of DR-TB Patients: Lost to Follow-up |
02/06/2024 |
DR-TB and PMDT |
| 1062 |
Causes for Drug-resistant Tuberculosis |
02/06/2024 |
DR-TB and PMDT |
| 1014 |
Guidelines for Issuing Bedaquiline and Delamanid to the Patient |
02/06/2024 |
DR-TB and PMDT |
